Acura Pharmaceuticals, Inc. (ACUR) Issues Earnings Results
Acura Pharmaceuticals, Inc. (NASDAQ:ACUR) announced its earnings results on Monday. The specialty pharmaceutical company reported ($0.12) earnings per share for the quarter, Bloomberg Earnings reports. The company had revenue of $0.08 million for the quarter. Acura Pharmaceuticals had a negative net margin of 2,335.87% and a negative return on equity of 1,237.56%.
Acura Pharmaceuticals (NASDAQ ACUR) traded down $0.01 during trading hours on Tuesday, hitting $0.42. The stock had a trading volume of 388 shares, compared to its average volume of 12,379. The company has a quick ratio of 1.15, a current ratio of 1.25 and a debt-to-equity ratio of -7.29. Acura Pharmaceuticals has a 52-week low of $0.40 and a 52-week high of $1.40.
COPYRIGHT VIOLATION NOTICE: “Acura Pharmaceuticals, Inc. (ACUR) Issues Earnings Results” was reported by Watch List News and is owned by of Watch List News. If you are viewing this piece on another website, it was stolen and reposted in violation of US and international copyright laws. The correct version of this piece can be accessed at https://www.watchlistnews.com/acura-pharmaceuticals-inc-acur-issues-earnings-results/1702433.html.
Acura Pharmaceuticals Company Profile
Acura Pharmaceuticals, Inc is a pharmaceutical company. The Company is engaged in the research, development and commercialization of technologies and products intended to address medication abuse and misuse. The Company has discovered and developed three platform technologies, which can be used to develop multiple products.
Receive News & Ratings for Acura Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acura Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.